'I made the sign of victory for Siwar': Mother's relief as malnourished Gaza baby evacuated to Jordan
The cry was frail but I could hear Siwar Ashour even before she was carried out of the coach.
It was the cry of a voice that won't give up, of a child born in this war and who has now, for a while at least, managed to escape it.
In person six-month-old Siwar is tinier than any visual image can convey. She weighs 3kg (6.6lb) but should be twice that. Her mother, Najwa, 23, smiled as she described her feelings on crossing into Jordan on Wednesday, when her daughter was evacuated from Gaza with other Palestinian children. The first thing she noticed was the quiet.
"It feels like there is a truce," she told me. "We will spend our night without rockets and bombing with God's will."
Siwar was also accompanied by her grandmother Reem and her father Saleh who is blind.
"The first and last goal of this trip is Siwar," said Saleh. "We want to get her to a safe shore. I want to make sure she is safe and cured. She's my daughter, my own flesh and blood. And I'm so deeply worried about her."
It was Reem who carried Siwar off the bus onto Jordanian soil, forming her fingers into a V sign as she came.
"Until now I can't believe that I have arrived in Jordan. I saw King's Abdullah's photo at the border and I felt so happy I got off the bus and made the sign of victory…for the sake of Siwar."
Back in April when the BBC first filmed Siwar at Nasser hospital in southern Gaza, her mother and doctor said she was suffering from malnutrition because the special milk formula she needed could not be found in sufficient quantity. Her body was emaciated. Najwa said then she could not breastfeed Siwar because she herself was suffering from malnutrition.
Tins of milk formula were found and delivered by the Jordanian Field hospital and by private fundraisers. But with an Israeli blockade on aid, which was partially eased three weeks ago, and an escalating military offensive it was clear Siwar's condition needed more comprehensive testing and treatment.
In a deal announced between King Abdullah and US President Donald Trump in February, Jordan offered to bring 2000 seriously ill children to Amman for treatment.
Gaza's devastated medical system cannot cope with the level of sickness and war wounded. Since March, 57 children along with 113 family escorts have been evacuated. Sixteen children came on Wednesday, including Siwar.
Cradled in her grandmother's arms, Siwar stared with her large eyes at the unfamiliar crowds of police, medical workers, and journalists gathered on the border.
She was taken to an air conditioned hall where Jordanian medics handed out drinks and food to the children. There was peace and plenty.
What was most obvious was the exhaustion of parents and children alike. In several months of covering these evacuations this latest was the most striking in terms of a sense of communal trauma.
All of these families know what it is to be driven from one area to another by Israeli evacuation orders, or to queue for hours in the hope of finding food. If they have not experienced death in their family, they will definitely know friends or relatives who have been killed.
Families are often separated by conflict as parents search for food or medical treatment. One day Najwa took Siwar to hospital and that was the last time husband Saleh was with them for two months.
"I thought she would be gone for just three or four days and then come back, a simple treatment and she'd return," he recalled. "But I was shocked that it dragged on and took so long…and eventually I realised that her condition is very serious and difficult."
We travelled from the border to Amman with Siwar and her family. Najwa is pregnant and fell into a deep sleep. Siwar remained awake in her grandmother's arms. On the same ambulance were two boys suffering from cancer, along with their mothers and two younger siblings. One of the siblings, a boy of four, cried constantly. He was tired and scared.
After an hour we reached Amman and Siwar was transferred into the arms of a nurse and then to another ambulance. Over the next few days she will be tested and given the kind of treatment that is simply impossible under current conditions in Gaza. And her mother, father and grandmother - those who watch over her - will sleep without fear.
WIth additional reporting by Alice Doyard, Suha Kawar, Mark Goddard and Malaak Hassouneh.
'Situation is dire' - BBC returns to Gaza baby left hungry by Israeli blockade
'No food when I gave birth': Malnutrition rises in Gaza as Israeli blockade enters third month
Gaza now worse than hell on earth, humanitarian chief tells BBC

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
World-first blood cancer therapy to be given on NHS
A "Trojan horse" therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world first. It can halt the blood cancer myeloma for nearly three times longer than current therapies. The drug is an advanced form of chemotherapy that hits cancer with a bigger dose, while reducing side-effects. Paul Silvester, one of the first people to get it, says the therapy has been "life-changing" and he's now planning history-themed adventures. Myeloma – also known as multiple myeloma – affects part of the immune system called plasma cells. These are made in the spongey bone marrow in the centre of our bones. Paul, who is 60 and from Sheffield, was diagnosed nearly two years ago after the cancer led to broken bones in his back. He had a bone marrow transplant last year, but relapsed around Christmas. He has since been on the new therapy – called belantamab mafodotin – as part of an early access scheme. Within weeks he was in remission. Other treatments could have left him isolating in his bedroom for months, so Paul says the therapy "is absolutely life-changing" and was "creating that opportunity to enjoy" life. Visiting Hadrian's Wall is next on the agenda for history buff Paul; and he's looking forward to one of his daughters graduating later this year. "Most people say 'you look really really well'... I have a good normal life," he told the BBC. Paul's therapy - belantamab mafodotin – is a lethal chemotherapy drug that has been bound to an antibody, similar to the ones the body uses to fight infection. However, these antibodies have been designed to spot markings on the outside of plasma cells. So they travel to cancerous cells, stick to the surface and are then absorbed. Once inside they release their toxic payload, to kill the cancer. The therapy is named Trojan horse therapy after the siege of the city of Troy in Greek mythology, when a giant wooden horse was used to smuggle soldiers into the city. Myeloma cannot be cured, but clinical trials last year showed the Trojan horse therapy halted the cancer for three years, compared to 13 months with current therapies. Prof Peter Johnson, the national clinical director for cancer at NHS England, said the difference was "life-changing". He told me: "This is a really important development for people with myeloma, because although we may not be able to cure the illness, giving them time free of the disease and free of the symptoms is really important. "We've seen in the last few years that using antibodies to deliver chemotherapy drugs directly into cells can make a big difference for a variety of different types of cancer." Around 33,000 people are living with myeloma in the UK. The new drug will be used when the first-choice therapy fails, so around 1,500 patients a year could benefit. The decision comes after a review by the National Institute of Health and Care Excellence (NICE) concluded the drug was cost-effective for NHS use. NICE recommendations are normally adopted in England, Wales and Northern Ireland while Scotland has its own process. The therapy is kinder than other cancer treatments, but is not free from side-effects. After a cancer cell has been destroyed, the remaining chemotherapy drug will leak into the body. This can cause dry eyes and blurred vision. The technical name for these drugs is an antibody-drug-conjugate. This therapy was developed by GSK in the UK with early research taking place in Stevenage and the first clinical trials in London. Prof Martin Kaiser, team leader in myeloma molecular therapy at the Institute of Cancer Research, said these "are very smart drugs" and the difference in side effects compared to other drugs "is really remarkable". While myeloma is still considered an incurable cancer, Prof Kaiser says drugs like this are "an important step towards a functional cure" and he thinks long-term remission will go "above 50% in the next five years". Antibody drug conjugates are being developed for a range of cancers. The limitation is being able to design an antibody that can target the cancer alone. There is one that can target some types of breast cancer. Research is already taking place on stomach and bowel cancer. Shelagh McKinlay, from the charity Myeloma UK, said the approval would "transform the lives of thousands" and it was "fantastic to see the UK at the forefront of myeloma treatment". Health Minister Karin Smyth, said: "This ground-breaking therapy puts the NHS at the forefront of cancer innovation." Exercise improves colon cancer survival, major study shows Breakthrough cancer drug doubles survival in trial
Yahoo
10 hours ago
- Yahoo
Over 100 reported killed in Gaza in 24 hours as telecoms go down
More than 100 people were reported killed in Israeli strikes on Gaza within 24 hours, as deadly incidents near aid distribution sites and a major communications outage deepened the crisis in the war-shattered Palestinian territory on Thursday. The Health Ministry in Gaza, controlled by Hamas, reported 103 deaths and 427 injuries in the past day alone. The ministry does not distinguish between civilians and combatants, and the figures could not be independently verified. Since the start of the war on October 7, 2023, which was triggered by a Hamas-led attack on southern Israel that killed around 1,200 people and saw more than 250 taken hostage, more than 55,200 people have been killed in Gaza and over 127,800 injured, according to the ministry. Palestinians reported that Israeli forces opened fire near aid distribution positions, while a humanitarian foundation said Hamas launched a deadly attack on its staff. The Palestinian news agency WAFA said at least 13 people were killed and around 200 injured at an aid centre in the Netzarim Corridor in central Gaza. The Hamas-run Health Ministry confirmed the incident, but put the toll at 10 dead and at least 120 wounded. Separately, WAFA reported five more deaths in the Sudaniya area north-west of Gaza City, where people were waiting for food assistance. The Israeli military has not commented on the incidents. The Gaza Humanitarian Foundation (GHF), supported by Israel and the United States, began distributing aid last month following a near three-month Israeli blockade. The initiative aims to prevent Hamas from diverting aid, according to Israeli officials. However, the operation has drawn criticism from the UN and humanitarian organizations, who cite safety and access concerns. The GHF said that a Hamas attack on one of its staff buses killed eight Palestinian employees and injured several others on Wednesday evening. The team was en route to a distribution centre west of Khan Younis in southern Gaza. The foundation stated that some employees may have been taken hostage and that it was still gathering information. "These were aid workers. Humanitarians. Fathers, brothers, sons, and friends," GHF said, condemning what it called a "heinous and deliberate attack." The organization urged the international community to hold Hamas accountable, saying its staff had been targeted simply for delivering food to Palestinians. WAFA, citing medical sources, reported that 224 people have been killed and over 1,850 injured around aid distribution points since May 27. 'The points have become traps for mass killings,' the agency said. Communications blackout adds to chaos Also on Thursday, Gaza's last functioning fibre-optic network was damaged in an attack, resulting in a complete outage of internet and landline services, according to the Palestinian Telecommunications Authority. WAFA said the blackout would have severe humanitarian and social consequences and called for immediate restoration. Telecommunications have been repeatedly disrupted during the conflict, hampering relief coordination and civilian communication. Israel has been engaged in a sustained military campaign in Gaza for 20 months, with the stated goal of eliminating Hamas and securing the release of remaining hostages. A new major ground offensive was launched nearly a month ago. The campaign has drawn international criticism, including from Israel's close allies, over the mounting civilian toll and the humanitarian situation on the ground.
Yahoo
11 hours ago
- Yahoo
Apex Labs Granted Israel MoH Approval to Expand Phase 2b Macrodose Psilocybin PTSD Clinical Trial
Israel's Ministry of Health (MoH) approval to add additional sites to APEX SUMMIT-90 160 patient phase 2b macrodose clinical trial: Tel Aviv University (TAU)'s Institute for Psychedelic Research located at the Sagol Brain Institute (SGI) in Tel-Aviv Sourasky Medical Center. Be'er Yaakov Mental Hospital (Merhavim) Center for Psychedelic Studies. For more information or to register visit (Canada) and (Israel). VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with psilocybin is pleased to announce the approval by the Israeli MoH and IRBs to open two additional clinical trial sites for SUMMIT-90. The trial is a double-blind, placebo controlled phase 2b study evaluating multiple doses of APEX-90, a psilocybin macrodose utilizing APEX's US patent pending capsule. APEX-90 is administered in-clinic with study-assisted psychotherapy for severe depression within diagnosed PTSD. Israel is facing a severe mental health crisis: 44% of adults report depression and 42% PTSD, far above the 8–13% depression and 6–10% PTSD rates seen in the US and Canada. This MoH approval leverages the expertise of TAU's renowned SGI and Merhavim Hospital, which both have a rich history of pioneering research in neurological sciences. Their cutting-edge facilities and teams profound understanding of PTSD dynamics are poised to add patient recruitment expertise. 'I am honoured to have been able to facilitate this new partnership; another example of building important bridges between Canada and Israel in innovative clinical research, which will result in advancing patient access to emerging treatments,' says Sharon J. Fraenkel, TAU Canada's CEO for Ottawa, Quebec, and Atlantic Canada, on behalf of the organization. 'As someone deeply connected to Israel, witnessing the toll of PTSD among my loved ones, I'm driven to lead research that brings hope and healing,' says Alysa Langburt, APEX's VP of Global Clinical Development. 'This marks more than a clinical milestone, it represents a fundamental step towards transforming the mental health landscape in Canada and Israel, where the need has never been greater. Through our incredible partnerships, we aim to catalyze a shift in access, care and outcomes for those suffering with PTSD.' "SUMMIT-90 offers a beacon of hope for the significant numbers suffering from PTSD in Canada and Israel,' says Tyler Powell, co-Founder and CEO of APEX. 'It underscores our commitment to global mental health innovation and our belief in the opportunity for clinically proven psilocybin therapies to transform mental health care.' About Apex Labs is a patient-driven pharmaceutical company focused on revolutionizing the standard of mental health care with psilocybin. APEX's strategy is two-pronged, clinical evaluation of drug assets alongside a robust Early Access Program. APEX recognizes and prioritizes Veterans as a patient base with the most severe unmet medical need. Visit for more information and follow APEX on LinkedIn, Twitter and Instagram. Forward-Looking StatementsThis release contains certain "forward-looking statements" and certain "forward-looking information" as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue", "plans" or similar terminology. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability to control or predict, that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out here in, including but not limited to: receiving authorization of Health Canada Dealers Licence; filing US provisional patent, the Company evaluating the safety and efficacy of APEX-52 (psilocybin) and APEX-90 (psilocybin) in treating depression in Veterans and patients with Post-Traumatic Stress Disorder; statements related to APEX-52 and APEX-90, including manufacturing, dosing, and trial details; statements made by the Company's executives with respect to Health Canada's Dealer's Licence and capsule patent filing; the Company's efforts around the Early Access Program; statements made relating to Canadian Veteran patients; approvals by the Israeli Ministry of Health and ethics; the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements' best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. SOURCE Apex Labs Ltd. CONTACT: For further information: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data